You are here

Article Text

Article menu
Unexpected outcome (positive or negative) including adverse drug reactions
Ischaemic stroke in a patient on sunitinib
  1. Maire Therese Lonergan1,
  2. Feargal Kellehar2,
  3. Raymond McDermott2,
  4. Ronan Collins1
  1. 1Adelaide & Meath Hospital, Stroke Unit and Department of Gerontology, Tallaght, Dublin, D24, Ireland
  2. 2Adelaide and Meath Hospital, Oncology, Tallaght, Dublin, D24, Ireland
  1. Correspondence to Ronan Collins, Ronan.Collins2{at}amnch.ie

Summary

Concerns have been raised about possible theoretical risk of thrombosis and bleeding with sunitinib (anti-vascular endothelial cell growth factor agent) therapy used for treatment of metastatic renal cell carcinoma. We present the first case of stroke in an older man with metastatic renal cell carcinoma, on sunitinib therapy.

https://doi.org/10.1136/bcr.01.2009.1420

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Competing interests: None.